拟参与建设深圳市细胞与基因治疗市场化公共服务平台，卫光生物盘中涨逾8%

Core Viewpoint - The stock price of Weiguang Biological (002880) surged over 8% following the announcement of a strategic partnership to establish a new company focused on cell and gene therapy services [1] Group 1: Company Announcement - Weiguang Biological announced plans to jointly invest with Shenzhen Shenye Biological Pharmaceutical Industry Development Co., Ltd., Shenzhen Cell Valley Biological Pharmaceutical Co., Ltd., and Shenzhen Saiqiao Biological Innovation Technology Co., Ltd. to establish Shenzhen Xihe Life Technology Co., Ltd. [1] - The initial registered capital of the new company is set at 100 million yuan, with Weiguang Biological contributing 40 million yuan, representing a 40% equity stake [1] Group 2: Strategic Implications - This project is a significant strategic move for Weiguang Biological, allowing the company to extend its core advantages from blood products into the cutting-edge field of biomedicine [1] - The initiative is expected to enhance the company's strategic layout in the biomedicine sector, cultivate new business growth points, and strengthen its competitive advantages [1] - The establishment of this platform is seen as a crucial step for the company to achieve strategic upgrades and promote high-quality development [1]